东瑞股份(001201) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥346,118,845.38, representing an increase of 87.55% compared to the same period last year[8] - Net profit attributable to shareholders was ¥64,044,300.44, a significant increase of 1,293.40% year-on-year[8] - The basic earnings per share for the quarter was ¥0.3010, up 1,293.52% from the previous year[8] - Total operating revenue for Q3 2022 was CNY 807.24 million, a decrease of 3.3% compared to CNY 839.25 million in Q3 2021[24] - Net profit for Q3 2022 was CNY 4.95 million, a significant decline from CNY 236.38 million in Q3 2021, representing a decrease of 97.9%[25] - The total comprehensive income for the period was CNY 4,950,308.51, with a total for the previous period of CNY 236,375,158.19[26] - Basic and diluted earnings per share for the period were CNY 0.0233, compared to CNY 1.2496 for the previous period[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,467,725,194.02, reflecting a growth of 21.71% compared to the end of the previous year[8] - The company's total assets as of September 30, 2022, amounted to CNY 4.47 billion, an increase of 21.6% from CNY 3.67 billion at the beginning of the year[22] - Current liabilities totaled CNY 624.00 million, up 83.8% from CNY 339.28 million in the previous year[22] - Long-term borrowings surged by 1778.13% to CNY 563,510,428.37 as a result of increased bank loans[14] - Long-term borrowings rose to CNY 563.51 million, compared to CNY 30.00 million in the same period last year, indicating a significant increase in leverage[22] - The company's total equity attributable to shareholders decreased by 0.99% to ¥3,066,961,657.67 compared to the previous year-end[8] - The total equity attributable to shareholders was CNY 3.07 billion, slightly down from CNY 3.10 billion at the beginning of the year, reflecting a decrease of 0.5%[22] Cash Flow - The company reported a net cash flow from operating activities of -¥56,005,017.60, a decrease of 135.20% year-on-year[8] - Cash flow from operating activities generated a net outflow of CNY -56,005,017.60, a significant decrease from CNY 159,113,366.54 in the previous period[29] - Cash inflow from investment activities totaled CNY 937,955,054.90, while cash outflow was CNY 2,228,298,387.34, resulting in a net cash outflow of CNY -1,290,343,332.44[30] - Cash flow from financing activities generated a net inflow of CNY 632,527,995.65, down from CNY 1,557,311,012.17 in the previous period[30] - The ending balance of cash and cash equivalents was CNY 251,780,618.04, a decrease from CNY 646,740,341.39 at the end of the previous period[30] - Cash and cash equivalents decreased to CNY 262.18 million from CNY 972.65 million at the beginning of the year, a decline of 73.0%[21] Inventory and Expenses - The company’s inventory increased by 40.40% to ¥391,970,281.28, primarily due to an increase in consumable biological assets[13] - Total operating costs increased to CNY 788.88 million, up 26.6% from CNY 623.09 million in the previous year[24] - R&D expenses increased by 30.57% to CNY 9,034,231.19 due to a rise in R&D personnel[14] - Research and development expenses for Q3 2022 were CNY 9.03 million, an increase of 30.6% from CNY 6.92 million in Q3 2021[24] - The company paid CNY 112,935,591.85 to employees, an increase from CNY 82,786,086.96 in the previous period[29] Other Financial Metrics - The company reported a significant increase in prepayments, which rose by 525.03% to ¥16,946,142.59, mainly due to increased advance payments for bulk raw materials[13] - Prepayments increased by 100% to CNY 40,000.03 due to an increase in rental prepayments[14] - Tax payable rose by 57.91% to CNY 6,965,182.96 primarily due to increased corporate income tax[14] - Other income grew by 125.85% to CNY 15,410,302.44 mainly from increased government subsidies[14] - Investment income turned negative at CNY -24,686,068.50, a decrease of 205.34% due to losses from joint ventures[14] Future Plans - The company plans to raise up to CNY 1,033 million through a non-public offering of A-shares, pending approval from the China Securities Regulatory Commission[18]